Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.37 |
| ▸ | PPARA | Q07869 | 5/20 | 0.37 |
| ▸ | PPARD | Q03181 | 5/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 3/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4534420 | 0.91 | ALDH1A1 (0.39) | PPARGPPARAPPARDSLC2A1HTR6 | |
| SCHEMBL4528728 | 0.90 | PPARG (0.39) | PPARGPPARAPPARDHTR6F10 | |
| SCHEMBL4528222 | 0.90 | PPARG (0.37) | PPARGPPARAPPARDHTR6F10 | |
| SCHEMBL4524381 | 0.88 | PPARG (0.36) | PPARGPPARAPPARDSLC2A1 | |
| SCHEMBL4536459 | 0.83 | PPARG (0.32) | PPARGPPARAPPARD | |
| SCHEMBL4514925 | 0.81 | PPARG (0.39) | PPARGPPARAPPARDHTR6F10 | |
| SCHEMBL4516479 | 0.81 | ALDH1A1 (0.39) | PPARGPPARAPPARDHTR6 | |
| SCHEMBL4527719 | 0.79 | PPARG (0.34) | PPARGPPARAPPARDSLC2A1 | |
| SCHEMBL4522978 | 0.79 | PPARG (0.37) | PPARGPPARAPPARDHTR6F10 | |
| SCHEMBL4535048 | 0.78 | PPARG (0.37) | PPARGPPARAPPARDHTR6F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076015-A1 | Tricyclic Spiro Compound Comprising Acyl Group Bound to Nitrogen Atom in the Ring | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-1864984-A1 | TRICYCLIC SPIRO COMPOUND COMPRISING ACYL GROUP BOUND TO NITROGEN ATOM IN THE RING | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076015-A1 | Tricyclic Spiro Compound Comprising Acyl Group Bound to Nitrogen Atom in the Ring | KCNH1, SCN1A, SCN10A | PPARG 2153/4885PPARA 1675/4885PPARD 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.